NCT00364676View on ClinicalTrials.gov

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2015

Study Completion Date

August 31, 2015

Conditions
TumorsHodgkins DiseaseNon-Hodgkins Lymphoma
Interventions
DRUG

VLI

Patients are dosed on Day 1 and Day 8 of a 21-day cycle.

DRUG

VLI

Patients are dosed on Day 1 of a 21-day cycle.

Trial Locations (3)

78229

Cancer Therapy and Research Center, San Antonio

South Texas Accelerated Research Therapeutics, San Antonio

H3T 1E2

McGill Centre for Translational Research in Cancer-Jewish General Hospital Clinical Research Unit, Montreal

All Listed Sponsors
lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT00364676 - Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | Biotech Hunter | Biotech Hunter